DICE Therapeutics
Dandan Yang has worked as a Scientist I in Medicinal Chemistry at DiCE Molecules since September 2021. Prior to that, they were a Research Scientist at WuXi AppTec from March 2020 to September 2021. From July 2019 to March 2020, they worked as a Polymer Chemist at X-Therma Inc. Dandan'searlier experience includes working as a Research Assistant at Stony Brook University from August 2013 to May 2019.
Dandan Yang completed their Bachelor's degree in Chemistry at Beijing Normal University from 2009 to 2013. Dandan then pursued higher education at Stony Brook University Graduate School, where they obtained a Doctor of Philosophy (Ph.D.) in Chemistry from 2013 to 2019.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.